Healthcare Industry News: OxyContin
News Release - February 21, 2007
Javelin Pharmaceuticals Names Derek Gallacher as European Managing Director
Accomplished Pain Sector Marketing Executive to Spearhead Dyloject(TM) Launch in EuropeCAMBRIDGE, Mass.--(HSMN NewsFeed)--Javelin Pharmaceuticals, Inc. (Amex: JAV ), a leading developer of novel products for pain control, named Derek Gallacher as European Managing Director. Based in Javelin's newly opened Cambridge, UK office, Mr. Gallacher brings over 20 years of successful pharmaceutical experience, including research roles with Beecham and Glaxo Pharmaceuticals. His pain sector sales & marketing experience began in 1993 at Napp Pharmaceuticals Ltd where he held a number of commercial roles. He was promoted in 2002 to a pan-European position at the related company Mundipharma International Ltd, where he was Director of European Analgesic Marketing and then European Marketing Director. Last year, Mr. Gallacher began his own highly successful consultancy and from July 2006 has been integral in setting up European operations on behalf of Javelin.
Mr. Gallacher will work with Mark Matthews, Javelin's Vice President for Commercial Affairs, to launch the Company's lead product, Dyloject, now under review for UK marketing approval for acute moderate-to-severe pain. Upon Dyloject's approval in the UK, the Company will file for marketing registration in other EU countries through the mutual recognition process. Dyloject is presently in Phase III clinical trials in the United States.
Mr. Gallacher will also manage Javelin's European operations, including the development of future European registration and marketing strategies for Javelin's two other late-stage product candidates: Rylomine(TM) (intranasal morphine) and PMI-150 (intranasal ketamine), each for the treatment of acute moderate-to-severe pain in differing patients and settings.
"The opportunity to launch Dyloject in Europe is exciting. There are clear patient and physician benefits with Dyloject, in an area of currently high unmet need" said Mr. Gallacher. "I look forward to working with Mark Matthews and the entire Javelin team as we grow the company together."
Mark Matthews commented, "Derek's depth of experience in the pharmaceutical industry is another step towards the commercial success of our lead product, Dyloject. His solid background in pharmacology, product marketing and sales, together with his long-standing relationships with key opinion leaders, make him perfectly suited to represent the Javelin brand in Europe."
About Mr. Gallacher
Immediately prior to joining Javelin, Mr. Gallacher headed his own consultancy where he leveraged his skills in the pharmaceutical industry to serve both domestic UK and international clients. While European Marketing Director for Mundipharma International, his duties spanned analgesic marketing, new product development and in-licensing. Prior to joining Mundipharma, he was Group Product Manager, Analgesics for Napp Pharmaceuticals, where he was responsible for its opioid franchise and led the marketing team that launched OxyContin® in the UK. In earlier positions, Mr. Gallacher was a pharmacologist for Glaxo Group Research and a research scientist at Beecham Pharmaceuticals. He holds a BSc (Honors) from the University of East London with a degree in Pharmacology, and has earned several academic awards in Applied Biology and Laboratory Sciences.
About Javelin
With US corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at www.javelinpharmaceuticals.com. JAV-G
Forward-looking Statement
This press release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
Source: Javelin Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
